Centers & Institutes

Although the Neurofibromatosis Therapeutic Acceleration Program (NTAP) is housed at Johns Hopkins University, we fund innovative investigators at research centers and institutes around the world. We continuously seek out individuals with the creativity and expertise required to develop therapies for cutaneous neurofibromas (cNFs), recruiting the most skilled investigators to our network.

Our partners include:

BioBasix, Inc.
Brigham and Women’s Hospital
Case Western Reserve University School of Medicine
Children’s Hospital of Philadelphia
Children’s National Health System
Children’s National Medical Center
Cincinnati Children’s Hospital
DoD
Galen, UK
Harvard University
Iconcologia
Indiana University
Innocentive
INSERM
Institute of Predictive and Personalized Medicine of Cancer (IMPPC), Spain
Memorial Sloan Kettering Cancer Center
Michigan State University College of Human Medicine
National Cancer Institute (NCI)
Northwestern University
Padova University
Rainbow Babies and Children’s Hospital
Riley Hospital for Children
SAGE Bionetworks
Spectrum Health Medical Group
The Brain Science Institute (BSi)
The Childhood Brain Tumor Foundation
The Children’s Tumor Foundation (CTF)
The European Medical Administration (EMA)
The FDA, Drug Development Tools (DDTs) Qualification Program
The NIH National Center for Advancing Translational Sciences (NCATS)
The NIH Office of Rare Diseases
The US Food and Drug Administration (FDA)
The Pediatric Oncology Branch of the National Cancer Institute (POB-NCI)
UCSF
UCLA
University of Alabama
University of Chicago
University of Florida
University of Manchester
University of Michigan
University of Milan
University of Tirkku
UT Southwestern
Van Andel Institute
Washington University
Wayne State University

Testimonial

What attracted me to NTAP is that “The NTAP was established to accelerate the development of effective treatments for plexiform neurofibromas.” I am passionate about helping NF1 patients. Through my basic research, I will have the opportunity to be involved with the development of innovative therapies for the treatment of plexiform neurofibromas and transfer the bench side research discoveries to clinical trials as quickly as possible, and eventually benefit plexiform neurofibroma patients.-- Jianqiang Wu, M.D., Ph.D.

Assistant Professor, UC Department of Pediatrics, Cincinnati Children's Hospital

NTAP focuses on the urgent and unmet need to promote novel therapies in plexiform neurofibromas. It leverages connections with academic, industry and government partners as well as strong advocates in the patient community to accelerate scientific research in this critical area and to draw talented young investigators to the field. It is uniquely positioned to change the landscape of NF care and plexiform treatment.-- Dr. Peter De Blank, M.D., M.A., M.S.C.E.

Pediatric Hematologist-Oncologist, Assistant Professor, Pediatrics, Case Western Reserve University School of Medicine

As the mother of a 16 year old son with multiple Plexiform Neurofibromas it is an honor to be representing the Neurofibromatosis Community on the NTAP Advisory Committee. Since he was 3 years old, my son has participated in numerous clinical trials with Dr. Brigitte Widemann at the NCI/NIH. We are encouraged that research is closer to bringing a safe and effective treatment for his Plexiform Neurofibromas. I am very hopeful that the NTAP initiative, spearheaded by some of the nation's most prominent NF authorities, will bring advancements to treatment options for NF patients throughout the world.-- Penny Freeman

Executive Advisory Committee, NTAP